Screener

Eligibility screening

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-

Sponsored by Merck Sharp & Dohme LLCStudy detailsClinicalTrials.gov

6 US sites in CA, NC, NY, PA

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.